Home > Insider Trading > Filing (0000950170-25-041546)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
2023658	Bicara Therapeutics Inc.	BCAX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1883986	Lara Meisner	116 Huntington Avenue, Suite 703 Boston MA 02116	Chief Legal Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-03-14	79,146	$5.45	79,145	No	4	M	Direct
Common Stock	Disposition	2025-03-14	48,526	$12.69	30,620	No	4	S	Direct
Common Stock	Disposition	2025-03-14	30,620	$13.24	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2025-03-14	48,720	$0.00	48,720	$5.45
Common Stock	Stock Option (Right to Buy)	Disposition	2025-03-14	30,246	$0.00	30,246	$5.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
107,187		2033-12-14	No	4	M	Direct
67,119		2033-12-14	No	4	M	Direct

Footnotes

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.05 to $13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.